CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $5.77.

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research report on Tuesday, January 7th.

CytomX Therapeutics Trading Up 0.8 %

Shares of CTMX stock opened at $0.89 on Tuesday. CytomX Therapeutics has a 12 month low of $0.83 and a 12 month high of $5.85. The firm has a market capitalization of $69.45 million, a price-to-earnings ratio of 5.22 and a beta of 1.03. The business’s 50-day moving average price is $1.05 and its 200-day moving average price is $1.16.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The company had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. During the same period last year, the company earned $0.04 earnings per share. On average, sell-side analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CTMX. US Bancorp DE bought a new stake in CytomX Therapeutics in the third quarter worth approximately $40,000. XTX Topco Ltd increased its holdings in CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares in the last quarter. Forefront Analytics LLC increased its holdings in CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 43,176 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $104,000. 67.77% of the stock is currently owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.